Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. With a workforce of over 63,000 people in 80 offices worldwide, Novo Nordisk markets products in 170 countries. Novo Nordisk’s purpose is to drive change to defeat serious chronic diseases, building upon its heritage in diabetes.
Novo Nordisk actively engages in Public-Private Partnerships together with industry, academia, and patient organisations. These partnerships utilise new technology, data, and tools to build a better understanding of disease and treatment areas. Working together with partners, Novo Nordisk seeks to support innovation across the clinical care pathway and improve patient outcomes.
Novo Nordisk is committed to improving the lives of people living with chronic diseases, and one way to do this is through early-stage disease detection and prevention. Novo Nordisk is proud to participate in GRIPonMASH, which aims to enable earlier and improved screening and diagnosis of those affected by MASLD/MASH at the primary care level.
